Clinical Trials Browser

Phase 1/2 × Interventional × tandutinib × Clear all

NCT00379080 2017-04-07

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

Phase 1/2 Completed

60 enrolled 22 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00297921 2013-11-06

A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute